Citations (107)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Phil McEwan, Marco Hafner, Vivekenand Jha, Ricardo Correa-Rotter, Gil Chernin, Luca De Nicola, Russell Villanueva, David C. Wheeler, Salvatore Barone, Stephen Nolan & Juan Jose Garcia Sanchez. (2023) Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis. Journal of Medical Economics 26:1, pages 1407-1416.
Read now
Read now
André J Scheen. (2023) Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?. Expert Review of Clinical Pharmacology 16:11, pages 1053-1062.
Read now
Read now
André J. Scheen. (2023) The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Review of Endocrinology & Metabolism 18:4, pages 271-282.
Read now
Read now
André J. Scheen. (2022) Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opinion on Drug Metabolism & Toxicology 18:6, pages 381-393.
Read now
Read now
Yang Yang, Jiu-liang Zhang & Qing Zhou. (2022) Targets and mechanisms of dietary anthocyanins to combat hyperglycemia and hyperuricemia: a comprehensive review. Critical Reviews in Food Science and Nutrition 62:4, pages 1119-1143.
Read now
Read now
André J Scheen & Pierre Delanaye. (2022) Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Review of Endocrinology & Metabolism 17:1, pages 35-46.
Read now
Read now
Lianglan Shen, Hongli Yang, Xingxing Fang, Huaxing Huang, Wubin Yao, Dongmei Chen & Yan Shen. (2021) A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population. Diabetes, Metabolic Syndrome and Obesity 14, pages 1621-1630.
Read now
Read now
André J. Scheen. (2021) Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opinion on Pharmacotherapy 22:16, pages 2149-2165.
Read now
Read now
Panagiotis-Nikolaos Lalagkas, Georgios Poulentzas, Christos Kontogiorgis & Antonios Douros. (2021) Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opinion on Drug Metabolism & Toxicology 17:6, pages 697-705.
Read now
Read now
André J Scheen. (2020) SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients. Diabetes, Metabolic Syndrome and Obesity 13, pages 2765-2779.
Read now
Read now
Luiz Paulo José Marques, Nayanne Aguiar Mendonça, Lucas Müller, Ana Carolina Pereira Diaz André, Eugênio Pacelle Queiroz Madeira & Lygia Maria Soares Fernandes Vieira. (2020) Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes. Postgraduate Medicine 132:8, pages 697-701.
Read now
Read now
Karl Sebastian Johansson, David Peick Sonne, Filip Krag Knop & Mikkel Bring Christensen. (2020) What is on the horizon for type 2 diabetes pharmacotherapy? – An overview of the antidiabetic drug development pipeline. Expert Opinion on Drug Discovery 15:11, pages 1253-1265.
Read now
Read now
Hirotaka Watada, Toshimasa Yamauchi, Fumiko Yamamoto, Atsushi Taniguchi, Larisa Yarush, Clemens Heilmann & Atsutaka Yasui. (2020) Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials. Expert Opinion on Drug Safety 19:9, pages 1193-1202.
Read now
Read now
Erasmia Sampani, Pantelis Sarafidis & Aikaterini Papagianni. (2020) Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opinion on Drug Safety 19:6, pages 673-682.
Read now
Read now
André J Scheen. (2020) Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety 19:3, pages 243-256.
Read now
Read now
Bryce C Simes & Gordon G MacGregor. (2019) Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and Obesity 12, pages 2125-2136.
Read now
Read now
Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes & Ernest A. Adeghate. (2019) An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical
trials. Expert Opinion on Investigational Drugs 28:9, pages 811-820.
Read now
Read now
Articles from other publishers (90)
Stefan Gölz, Alexander Eckert, Fran Jürgen Wosch, Inge Hugenberg, Manuela Karl, Jochen Seufert, Heike Nun-Boetzel, Siegfried Wagner, Rosemarie Weber-Lauffer, Karsten Milek, Michael Naudorf & Reinhard Walter Holl. (2023) Verordnung von Antidiabetika und glykämische Kontrolle bei Erwachsenen mit Diabetes mellitus Typ 2 im zeitlichen Verlauf: Auswertung aus dem DPV-Register aus den Jahren 2005 bis 2021. Diabetologie und Stoffwechsel 18:06, pages 488-498.
Crossref
Crossref
Bernard Bauduceau, Lyse Bordier & Louis Monnier. (2023) Prise en charge médicamenteuse de la néphropathie diabétique. Médecine des Maladies Métaboliques 17:8, pages 644-653.
Crossref
Crossref
Sajad Khiali, Mohammadreza Taban‐Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy‐Aghdam, Afra Rezagholizadeh, Hila Asham & Taher Entezari‐Maleki. (2023) SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review. The Journal of Clinical Pharmacology 63:12, pages 1307-1323.
Crossref
Crossref
Vennela Avula, Garima Sharma, Mikhail N. Kosiborod, Muthiah Vaduganathan, Tomas G. Neilan, Teresa Lopez, Susan Dent, Lauren Baldassarre, Marielle Scherrer-Crosbie, Ana Barac, Jennifer Liu, Anita Deswal, Sumanth Khadke, Eric H. Yang, Bonnie Ky, Daniel Lenihan, Anju Nohria, Sourbha S. Dani & Sarju Ganatra. (2023) SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction. JACC: Heart Failure.
Crossref
Crossref
Jinfang Song, Xia Li & Jiang Ni. (2023) A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review. Kidney and Blood Pressure Research, pages 1-1.
Crossref
Crossref
Jiajia Wu, Hong Cai, Jia Xia, Tianyi Zhang, Jiayi Yan, Xinhua Shao, Amanda Ying Wang, Jianxiao Shen & Shan Mou. (2023) SGLT2i: Therapeutic options or contributing factors of contrast-induced acute kidney injury in the setting of non-diabetes?. Pharmacological Research 195, pages 106883.
Crossref
Crossref
Mauro Rigato, Gian Paolo Fadini & Angelo Avogaro. (2023) Safety of sodium‐glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism.
Crossref
Crossref
Tomoya Shintani, Hideya Shintani, Masashi Sato & Hisashi Ashida. (2023) Calorie restriction mimetic drugs could favorably influence gut microbiota leading to lifespan extension. GeroScience 45:6, pages 3475-3490.
Crossref
Crossref
Lixin Guo, Jing Wang, Li Li, Lin Yuan, Sheng Chen, Hui Wang, Tonghuan Li, Lin Qi & Hong Yang. (2023) A multicentre, prospective, non-interventional study evaluating the safety of dapagliflozin in patients with type 2 diabetes in routine clinical practice in China (DONATE). BMC Medicine 21:1.
Crossref
Crossref
Bela Patel, Lisa Pair & Michele Talley. (2023) Type 2 Diabetes: SGLT2i-Associated Genitourinary Infections and Lower Urinary Tract Dysfunction. The Journal for Nurse Practitioners 19:6, pages 104615.
Crossref
Crossref
Jose A. Adams, Jose R. Lopez, Veronica Banderas & Marvin A. Sackner. (2023) A Nonrandomized Trial of the Effects of Passive Simulated Jogging on Short-Term Heart Rate Variability in Type 2 Diabetic Subjects. Journal of Diabetes Research 2023, pages 1-11.
Crossref
Crossref
Munteanu Madalina Andreea, Swarnkar Surabhi, Popescu Razvan-Ionut, Ciobotaru Lucia, Nicolae Camelia, Tufanoiu Emil & Nanea Ioan Tiberiu. (2023) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. Medicina 59:4, pages 742.
Crossref
Crossref
André J. Scheen. (2023) Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes. Diabetes Epidemiology and Management 10, pages 100135.
Crossref
Crossref
André J. Scheen. (2023) Clinical pharmacology of antidiabetic drugs: What can be expected of their use?. La Presse Médicale 52:1, pages 104158.
Crossref
Crossref
André J. Scheen & Fabrice Bonnet. (2023) Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?. Diabetes & Metabolism 49:2, pages 101419.
Crossref
Crossref
Sonia Roldan Munoz, Douwe Postmus, Sieta T. de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans Hillege & Peter G. M. Mol. (2023) What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug Safety 46:3, pages 243-255.
Crossref
Crossref
Jaime A Davidson, Norlela Sukor, Fen‐Lee Hew, Mafauzy Mohamed & Zanariah Hussein. (2022)
Safety of sodium–glucose c
otransporter
2 inhibitors in Asian type 2 diabetes populations
. Journal of Diabetes Investigation 14:2, pages 167-182.
Crossref
Crossref
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui & Jinjun Guo. (2023) Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Frontiers in Endocrinology 13.
Crossref
Crossref
Lorenzo Pistelli, Francesca Parisi, Michele Correale, Federica Cocuzza, Francesca Campanella, Tommaso de Ferrari, Pasquale Crea, Rosalba De Sarro, Olga La Cognata, Simona Ceratti, Tonino Recupero, Gaetano Ruocco, Alberto Palazzuoli, Egidio Imbalzano & Giuseppe Dattilo. (2023) Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy—A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure. Journal of Clinical Medicine 12:1, pages 379.
Crossref
Crossref
Jonali Ramani, Harshil Shah, Vivek K. Vyas & Manmohan Sharma. (2022) A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present. European Journal of Medicinal Chemistry Reports 6, pages 100074.
Crossref
Crossref
Tilmann Kramer, Paul Brinkkoetter & Stephan Rosenkranz. (2022) Right Heart Function in Cardiorenal Syndrome. Current Heart Failure Reports 19:6, pages 386-399.
Crossref
Crossref
Hibathulla Palapra, Subeesh K. Viswam, Vivekanandan Kalaiselvan & Krishna Undela. (2022) SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports. International Journal of Clinical Pharmacy 44:6, pages 1425-1433.
Crossref
Crossref
Rena Pollack & Avivit Cahn. (2022) SGLT2 Inhibitors and Safety in Older Patients. Heart Failure Clinics 18:4, pages 635-643.
Crossref
Crossref
Wei Huang, Yi-Yuan Chen, Zi-Qi Li, Fang-Fang He & Chun Zhang. (2022) Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences 23:18, pages 10882.
Crossref
Crossref
Wajd Alkabbani, Arsène Zongo, Jasjeet K. Minhas‐Sandhu, Dean T. Eurich, Baiju R. Shah, Mhd. Wasem Alsabbagh & John‐Michael Gamble. (2022) Five comparative cohorts to assess the risk of genital tract infections associated with sodium‐glucose cotransporter‐2 inhibitors initiation in type 2 diabetes mellitus. Diabetic Medicine 39:8.
Crossref
Crossref
Thaer Idrees, Iris A Castro-Revoredo, Alexandra L Migdal, Emmelin Marie Moreno & Guillermo E Umpierrez. (2022) Update on the management of diabetes in long-term care facilities. BMJ Open Diabetes Research & Care 10:4, pages e002705.
Crossref
Crossref
Hongyan Liu, Vikas S. Sridhar, Bruce A. Perkins, Julio Rosenstock & David Z. I. Cherney. (2022) SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. Current Diabetes Reports 22:7, pages 317-332.
Crossref
Crossref
Irina Claudia Anton, Liliana Mititelu-Tartau, Eliza Gratiela Popa, Mihaela Poroch, Vladimir Poroch, Delia Reurean Pintilei & Gina Eosefina Botnariu. (2022) Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes. Healthcare 10:7, pages 1153.
Crossref
Crossref
Adnan A. Zainal & Marwan M. Merkhan. (2022) IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW. Military Medical Science Letters 91:2, pages 140-160.
Crossref
Crossref
Beini Lyu, Tripti Singh & Brad C. Astor. (2022) Epidemiology and Outcomes for the Chronic Kidney Disease. Nephrology Self-Assessment Program 21:2, pages 121-134.
Crossref
Crossref
André J. Scheen. (2022) Inhibiteurs des SGLT2 et risque d’amputations des membres inférieurs : plus de peur que de mal ?. Médecine des Maladies Métaboliques 16:4, pages 336-342.
Crossref
Crossref
André J. Scheen. (2022) Choix entre une gliptine et une gliflozine chez le patient âgé avec un diabète de type 2. Médecine des Maladies Métaboliques 16:3, pages 264-270.
Crossref
Crossref
Andre J. Scheen. (2022) Lower-limb amputations in patients treated with SGLT2 inhibitors versus DPP-4 inhibitors: A meta-analysis of observational studies. Diabetes Epidemiology and Management 6, pages 100054.
Crossref
Crossref
Justin T. CallPedro CortésDana M. Harris. (2022) A practical review of diabetes mellitus type 2 treatment in primary care. Romanian Journal of Internal Medicine 60:1, pages 14-23.
Crossref
Crossref
André J Scheen & Pierre Delanaye. (2022) Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers. Diabetes & Metabolism 48:2, pages 101315.
Crossref
Crossref
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu & Jianhua Mao. (2021) Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns. Nephrology 27:2, pages 126-132.
Crossref
Crossref
Shufei Zeng, Denis Delic, Chang Chu, Yingquan Xiong, Ting Luo, Xiaoyi Chen, Mohamed M.S. Gaballa, Yao Xue, Xin Chen, Yaochen Cao, Ahmed A. Hasan, Kai Stadermann, Sandra Frankenreiter, Lianghong Yin, Bernhard K. Krämer, Thomas Klein & Berthold Hocher. (2022) Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet. Biomedicine & Pharmacotherapy 146, pages 112606.
Crossref
Crossref
Beini Lyu, Morgan E. Grams, Alex Chang, Lesley A. Inker, Josef Coresh & Jung-Im Shin. (2022) Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization. The American Journal of Cardiology 165, pages 124-130.
Crossref
Crossref
Bharathi Upadhya, Patrick M. Kozak, Richard Brandon Stacey & Ramachandran S. Vasan. (2022) Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage. Current Hypertension Reports 24:1, pages 1-20.
Crossref
Crossref
Xiang Zhou, Xiaofei Ye, Xiaojing Guo, Dongxu Liu, Jinfang Xu, Fangyuan Hu, Yinghong Zhai, Yongqing Gao, Xiao Xu, Ziwei Dong & Jia He. (2021) Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS. Frontiers in Pharmacology 12.
Crossref
Crossref
Caiyun Zheng, Meimei Lin, Yan Chen, Haiting Xu, Lingqun Yan & Hengfen Dai. (2021) Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Huayang Li, Yitao Zhang, Shunjun Wang, Yuan Yue, Quan Liu, Suiqing Huang, Huajing Peng, Yi Zhang, Weijie Zeng & Zhongkai Wu. (2021) Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. Frontiers in Pharmacology 12.
Crossref
Crossref
Sheldon H. Gottlieb. (2021) Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology 78:20, pages 2013-2016.
Crossref
Crossref
André J. Scheen. (2021) Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 47:6, pages 101275.
Crossref
Crossref
Samantha T. Harris, Elisabetta Patorno, Min Zhuo, Seoyoung C. Kim & Julie M. Paik. (2021) Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Diabetes Care 44:10, pages 2293-2301.
Crossref
Crossref
Mohit Chandrashekar, Stuart Philip, Alexander Nesbitt, Andre Joshi & Marlon Perera. (2021) Sodium glucose‐linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. International Journal of Urology 28:10, pages 984-990.
Crossref
Crossref
Marta Baviera, Stefano Genovese, Vito Lepore, Pierluca Colacioppo, Fabio Robusto, Mauro Tettamanti, Antonio D'Ettorre, Fausto Avanzini, Ida Fortino, Antonio Nicolucci, Maria C. Roncaglioni & Francesco Giorgino. (2021) Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Italian cohorts. Diabetes, Obesity and Metabolism 23:7, pages 1484-1495.
Crossref
Crossref
Pierre Delanaye & Andre J. Scheen. (2021) Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies. Diabetes Epidemiology and Management 3, pages 100021.
Crossref
Crossref
Kevin Baumgartner & Jason Devgun. (2021) Toxicology of Medications for Diabetes Mellitus. Critical Care Clinics 37:3, pages 577-589.
Crossref
Crossref
Vishnu Vardhan Garla, Javed Butler & Lillian F. Lien. (2021) SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. Current Cardiology Reports 23:6.
Crossref
Crossref
Thomas M. Caparrotta, Andrew M. Greenhalgh, Karen Osinski, Robert M. Gifford, Svenja Moser, Sarah H. Wild, Rebecca M. Reynolds, David J. Webb & Helen M. Colhoun. (2021) Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy 12:4, pages 991-1028.
Crossref
Crossref
Henrik V.B. Laursen, Johan B. Røikjer, Jakob Dal & Morten Hasselstrøm Jensen. (2021) Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use. Current Drug Safety 16:1, pages 73-81.
Crossref
Crossref
Aamer Ubaid, Awais Naeem & Farishta Waheed. (2021) Empagliflozin-Associated Fournier Gangrene. American Journal of Therapeutics 28:4, pages e495-e497.
Crossref
Crossref
André J. Scheen. (2021) Sulphonylureas in the management of type 2 diabetes: To be or not to be?. Diabetes Epidemiology and Management 1, pages 100002.
Crossref
Crossref
Aaron Y. Kluger. 2021. Textbook of Cardiorenal Medicine. Textbook of Cardiorenal Medicine
279
294
.
Mario Luca Morieri, Agostino Consoli, Giorgio Sesti, Francesco Purrello, Angelo Avogaro & Gian Paolo Fadini. (2020)
Comparative effectiveness of dapagliflozin vs
DPP
‐4 inhibitors on a composite endpoint of
HbA1c
, body weight and blood pressure reduction in the real world
. Diabetes/Metabolism Research and Reviews 37:1.
Crossref
Crossref
Francesco Giorgino, Jiten Vora, Peter Fenici & Anna Solini. (2020) Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology 19:1.
Crossref
Crossref
Martin R. Cowie & Miles Fisher. (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature Reviews Cardiology 17:12, pages 761-772.
Crossref
Crossref
Bernard Bauduceau & Lyse Bordier. (2020) La dapagliflozine (Forxiga® et Xigduo®). Médecine des Maladies Métaboliques 14:8, pages 744-753.
Crossref
Crossref
Ajitesh Roy, Animesh Maiti, Anirban Sinha, Arjun Baidya, Asish Kumar Basu, Dasarathi Sarkar, Debmalya Sanyal, Dibakar Biswas, Indira Maisnam, Kaushik Pandit, Moutusi Raychaudhuri, Nilanjan Sengupta, Partha Pratim Chakraborty, Pradip Mukhopadhyay, Pradip Raychaudhuri, Pranab Kumar Sahana, Purushottam Chatterjee, Rana Bhattacharjee, Ranen Dasgupta, Ravi Kant Saraogi, Salil Kumar Pal, Sarmishtha Mukhopadhyay, Satinath Mukhopadhyay, Soumik Goswami, Subhankar Chowdhury & Sujoy Ghosh. (2020) Kidney Disease in Type 2 Diabetes Mellitus and Benefits of Sodium-Glucose Cotransporter 2 Inhibitors: A Consensus Statement. Diabetes Therapy 11:12, pages 2791-2827.
Crossref
Crossref
N. V. Sturov, S. V. Popov, N. K. Mamporia & A. A. Mager. (2020) Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria. Terapevticheskii arkhiv 92:11, pages 106-109.
Crossref
Crossref
Kayla R. Stover, Emily Hugh, Justin J. Sherman, Scott S. Malinowski, Gideon J. Berdahl & Daniel M. Riche. (2020) Infectious complications of newer agents in the fight against diabetes. The Nurse Practitioner 45:11, pages 17-24.
Crossref
Crossref
Theocharis Koufakis, Omar G. Mustafa, Ramzi A. Ajjan, Xavier Garcia‐Moll, Pantelis Zebekakis, George Dimitriadis & Kalliopi Kotsa. (2020) The use of sodium‐glucose co‐transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. Journal of Clinical Pharmacy and Therapeutics 45:5, pages 883-891.
Crossref
Crossref
André J. Scheen. (2020) Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16:10, pages 556-577.
Crossref
Crossref
Francesco Giorgino, Jiten Vora, Peter Fenici & Anna Solini. (2020) Cardiovascular protection with sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism 22:9, pages 1481-1495.
Crossref
Crossref
Avivit Cahn, Itamar Raz, Marc Bonaca, Ofri Mosenzon, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, John P. H. Wilding, Deepak L. Bhatt, Darren K. McGuire, Ingrid A. M. Gause‐Nilsson, Martin Fredriksson, Peter A. Johansson, Gyorgy Jermendy, Samy Hadjadj, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott & Lawrence A. Leiter. (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study. Diabetes, Obesity and Metabolism 22:8, pages 1357-1368.
Crossref
Crossref
André J. Scheen. (2020) Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics 59:8, pages 981-994.
Crossref
Crossref
Patrice Darmon. (2020) Profil de tolérance des inhibiteurs de SGLT2 : le point en 2020. Médecine des Maladies Métaboliques 14:4, pages 331-341.
Crossref
Crossref
André J. Scheen. (2020) À propos de l’expérience belge avec les inhibiteurs des SGLT2. Médecine des Maladies Métaboliques 14:4, pages 320-330.
Crossref
Crossref
A.J. Scheen. (2020) SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?. Diabetes & Metabolism.
Crossref
Crossref
A.J. Scheen. (2020) Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes & Metabolism 46:3, pages 186-196.
Crossref
Crossref
N. Menghoum, P. Oriot, M.-P. Hermans & J.-L. Mariage. (2020) Cétose ou acidocétose diabétique euglycémique chez des patients diabétiques de type 2 traités par inhibiteurs du SGLT2 : une série de cas cliniques en Belgique. La Revue de Médecine Interne 41:4, pages 226-231.
Crossref
Crossref
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou & John Barbetseas. (2020) Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension. American Journal of Hypertension 33:3, pages 207-213.
Crossref
Crossref
Francesco Giorgino, Irene Caruso, Julia Moellmann & Michael Lehrke. (2020) Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, pages 154045.
Crossref
Crossref
Serge Halimi. (2020) Gangrène de Fournier. Rôle du diabète. Quelle responsabilité pour les inhibiteurs de SGLT2 ?. Médecine des Maladies Métaboliques 14:1, pages 21-28.
Crossref
Crossref
Robert J. Chilton. (2019) Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes. Diabetes, Obesity and Metabolism 22:1, pages 16-29.
Crossref
Crossref
Paul Valensi & Gaëtan Prévost. (2020) CVOTs: What did the endocrinologist learn?. Diabetes Research and Clinical Practice 159, pages 107947.
Crossref
Crossref
André J. Scheen. (2020) Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice 159, pages 107726.
Crossref
Crossref
Aaron Y. Kluger, Kristen M. Tecson, Andy Y. Lee, Edgar V. Lerma, Janani Rangaswami, Norman E. Lepor, Michael E. Cobble & Peter A. McCullough. (2019) Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Dario Giugliano & Katherine Esposito. (2019) Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Kashif Haider, Ankita Pathak, Ankit Rohilla, Md Rafi Haider, Kamal Ahmad & M. Shahar Yar. (2019) Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review. European Journal of Medicinal Chemistry 184, pages 111773.
Crossref
Crossref
Richard Ofori-Asenso, Danny Liew, Samanta Lalic, Mohsen Mazidi, Dianna J. Magliano, Zanfina Ademi, J. Simon Bell & Jenni Ilomaki. (2019) Adherence, Persistence, and Switching Among People Prescribed Sodium Glucose Co-transporter 2 Inhibitors: A Nationwide Retrospective Cohort Study. Advances in Therapy 36:11, pages 3265-3278.
Crossref
Crossref
Lidan Yang, Lin Zhang, He He, Mei Zhang & Zhenmei An. (2019) Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy 10:5, pages 1921-1934.
Crossref
Crossref
Anjali Kumar & Erik Stiles. (2019) Perineal soft tissue infections. Seminars in Colon and Rectal Surgery 30:3, pages 100692.
Crossref
Crossref
Clifford J. Bailey & Caroline Day. (2019) The future of new drugs for diabetes management. Diabetes Research and Clinical Practice 155, pages 107785.
Crossref
Crossref
A.J. Scheen, P. Darmon & H. Hanaire. (2019) Assessment of the benefit–risk balance of SGLT2 inhibitors: Commentary on a new ‘French paradox’. Diabetes & Metabolism 45:4, pages 319-321.
Crossref
Crossref
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou & Nikolaos Tentolouris. (2019) SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects. International Journal of Environmental Research and Public Health 16:16, pages 2965.
Crossref
Crossref
A.J. Scheen. (2019) Solutions thérapeutiques pour un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine. Médecine des Maladies Métaboliques 13:3, pages 272-279.
Crossref
Crossref
Bernard Bauduceau, Lyse Bordier, Jacques Bringer, Gérard Chabrier, Bernard Charbonnel, Emmanuel Cosson, Patrice Darmon, Bruno Detournay, Pierre Fontaine, Pierre Gourdy, André Grimaldi, Bruno Guerci, Hélène Hanaire, Alfred Penfornis, Jean-Pierre Riveline & André Scheen. (2019) Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2. Médecine des Maladies Métaboliques 13:2, pages 195-209.
Crossref
Crossref
Sumanta Saha & Sujata Saha. (2019) A Systematic Review and Meta-Analysis of Randomised Controlled Trials, Contrasting the Safety Profile between Sodium-Glucose Cotransporter-2 Inhibitors and Placebo in Type 1 Diabetes Mellitus Patients. Dubai Diabetes and Endocrinology Journal 25:3-4, pages 62-73.
Crossref
Crossref